BiotechTube
KCAS Bioanalytical

KCAS Bioanalytical

Shawnee, United States· Est.
kcasbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

KCAS Bio is a well-established, privately-held bioanalytical CRO that serves as a critical partner to pharmaceutical and biotech companies worldwide. The company differentiates itself through deep technical expertise, a consultative approach, and significant investments in harmonized, cutting-edge instrumentation like spectral flow cytometry. With a proven track record of quality, including over 20 successful FDA audits with no major findings, KCAS Bio focuses on minimizing development delays and providing reliable, error-free data to advance client programs efficiently.

Diagnostics

Technology Platform

Integrated bioanalytical services platform featuring globally harmonized spectral flow cytometry (Cytek), ligand binding assays (LBA), liquid chromatography-mass spectrometry (LC-MS/MS), biomarker, immunogenicity, cellular, and molecular assay capabilities, supported by clinical kitting and sample management.

Funding History

1
Total raised:$15M
Series A$15M

Opportunities

Growing demand for specialized bioanalytical support for complex therapeutic modalities (cell/gene therapy, biologics) drives market expansion.
The trend toward outsourcing and the need for globally harmonized laboratory data in multi-regional clinical trials present significant growth avenues.
Its established reputation for quality and regulatory success positions it as a partner of choice for de-risking late-stage development.

Risk Factors

Revenue is vulnerable to cyclical swings in biopharma R&D spending and biotech funding.
The company operates in a highly competitive CRO market with pressure from large full-service players and other niche labs.
Operational risks include regulatory compliance failures, talent retention challenges, and the need for continual capital investment to avoid technological obsolescence.

Competitive Landscape

KCAS Bio competes in the specialized bioanalytical segment of the broader CRO market. Key competitors include large, full-service CROs with bioanalytical divisions (e.g., LabCorp, IQVIA) and other focused bioanalytical labs. Its differentiation is based on deep technical expertise, a consultative partnership model, a strong quality record, and unique capabilities like globally harmonized spectral flow cytometry.

More companies in Digital Health & Biotech SaaS →More companies in United States →